Full-Time

Acute Care Specialist

Houston East

ANI Pharmaceuticals

ANI Pharmaceuticals

501-1,000 employees

Develops, manufactures, markets prescription drugs

Compensation Overview

$140k - $170k/yr

+ Short-term Incentive + Long-term Incentive

Houston, TX, USA

Hybrid

Must travel 40-60% overnight; remote within the United States.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Cold Calling

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor’s degree required; RN or clinical background a plus but not required for candidates with strong access-driven sales experience.
  • Minimum 3+ years of experience in pharmaceutical and/or medical device sales.
  • Experience working with Primary Care, Podiatry, or Orthopedic practices is strongly preferred.
  • Ability to travel overnight (40–60%) depending on territory needs.
  • Valid driver’s license required.
Responsibilities
  • Promote ANI’s PCG for Acute Gouty Arthritis through clinical education and strategic engagement with targeted HCPs.
  • Build and execute territory-specific plans to drive physician awareness, patient identification, and market growth.
  • Educate providers and staff on treatment access, insurance coverage, and documentation requirements.
  • Coordinate with internal teams including Market Access, Patient Support Services, and Medical Affairs to ensure seamless patient onboarding and therapy initiation.
  • Maintain detailed communication logs and follow-up documentation to support continuity of care.
  • Cold call and engage new accounts across Primary Care, Podiatry, and Orthopedics.
  • Collaborate with cross-functional teams to ensure logistical readiness and patient support.
  • Contribute to building and scaling a new commercial footprint within an expanding Acute Care business.
  • Demonstrate compliance and integrity in all interactions.
Desired Qualifications
  • Familiarity with specialty distribution and patient support services is a plus.

ANI Pharmaceuticals develops, manufactures, and markets prescription medications, including generic and branded products, that are FDA-approved. Its medicines are produced in regulated facilities and go through standard safety and efficacy testing to meet patient needs. The company sells these products to pharmacies, hospitals, and healthcare providers, using a portfolio that spans generic drugs and specialty branded therapies. What sets ANI apart is its combination of a diversified product lineup with growth through strategic acquisitions to expand its offerings and market reach, rather than relying on a single product area. Its goal is to provide high-quality medicines to patients while continuously expanding its portfolio and market presence through acquisitions and manufacturing capabilities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Baudette, Minnesota

Founded

1996

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $266 million, and management reaffirmed $1.08-$1.14 billion guidance.
  • July 2026 was the highest month for new Cortrophin cases, signaling demand acceleration.
  • Repurchased-capable cash generation reached $360.2 million, funding acquisitions and buybacks through May 2029.

What critics are saying

  • Cortrophin 2026 guidance fell to $520-$540 million, exposing second-half execution risk.
  • Merck royalty burden stays in the high-20% range, compressing Cortrophin margins.
  • CG Oncology litigation still lingers after the July 29, 2025 no-damages verdict, risking distraction.

What makes ANI Pharmaceuticals unique

  • Cortrophin Gel drove 43.5% Q2 2026 growth, with rare disease becoming ANI's core.
  • ANI pairs U.S. manufacturing with 116 products, supporting branded, generic, and specialty breadth.
  • Henry Gosebruch joined August 19, 2026, bringing AbbVie M&A discipline to transformation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

23%
Yahoo Finance
Aug 28th, 2026
ANI Pharmaceuticals shows 36% revenue growth but limited scale at $978M

ANI Pharmaceuticals trades at $76.15 per share, showing a 3% return over six months, underperforming the S&P 500's 11.7% gain. The company develops, manufactures, and markets branded and generic prescription pharmaceuticals with a portfolio of 116 products. The pharmaceutical firm demonstrated strong momentum with revenue growing at 35.6% compound annual growth rate over five years. Its free cash flow margin expanded by 38.5 percentage points during the same period, reaching 17.7% over the trailing 12 months. However, ANI Pharmaceuticals faces scale challenges with just $978.4 million in revenue over the past year. This smaller size limits its ability to build customer trust in the heavily regulated healthcare sector, though it allows for faster potential growth with proper execution.

Yahoo Finance
Aug 24th, 2026
ANI Pharmaceuticals targets $1.6B market cap with 34.7% revenue growth, while Revolve and ProPetro face challenges

ANI Pharmaceuticals, a developer and marketer of branded and generic prescription drugs with a focus on rare disease treatments, stands out among Russell 2000 stocks. The company's portfolio includes 116 pharmaceutical products. ANI delivered 34.7% annual revenue growth over the past two years, indicating market share gains. Earnings per share increased 19.9% annually over five years, outperforming peers. The company's free cash flow margin improved by 38.5 percentage points over five years, providing resources for growth initiatives, share buybacks, or dividends. Meanwhile, fashion retailer Revolve and hydraulic fracturing services provider ProPetro face challenges. Revolve's 6.6% annual sales growth and 6.5% customer growth over three years underperformed, whilst high marketing expenses suggest heavy spending on customer acquisition. ProPetro's modest revenue base and declining EBITDA margin limit its competitiveness.

Yahoo Finance
Aug 24th, 2026
ANI Pharmaceuticals appoints Henry Gosebruch to board amid rare disease company transformation

ANI Pharmaceuticals has appointed Henry Gosebruch to its board of directors, effective 19 August 2026. Gosebruch brings over 30 years of experience in corporate strategy, business development, and finance across the biopharmaceutical sector. He currently serves as chief executive officer of Lakefront Biotherapeutics and previously held leadership positions at Neumora Therapeutics and AbbVie, where he oversaw more than 100 transactions including AbbVie's acquisition of Allergan. Before that, he spent over 20 years at J.P. Morgan as co-head of North American M&A. The appointment aims to strengthen ANI's board as the company accelerates its transformation into a rare disease-focused business. Muthusamy Shanmugam has resigned from the board but will continue as head of research and development and chief operating officer of New Jersey operations.

Yahoo Finance
Aug 16th, 2026
ANI Pharmaceuticals beats Q2 estimates with $266M revenue despite market concerns over Cortrophin guidance

ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million with 25.9% year-on-year growth. The company's adjusted EPS of $2.21 also surpassed expectations of $2.04. Despite strong performance in rare disease and generics businesses, the market reacted negatively to the results. CEO Nikhil Lalwani highlighted momentum in the third quarter, noting July marked the highest month for new cases initiated. The company reconfirmed its full-year revenue guidance of $1.11 billion at the midpoint and maintained its adjusted EPS guidance of $9.44. Operating margin improved to 15.2%, up from 6.6% in the same quarter last year. Analysts questioned the disconnect between prescription data and revenue, insurance reverification issues, and the rationale behind lowering Cortrophin guidance despite positive demand metrics.

Yahoo Finance
Aug 15th, 2026
ANI Pharmaceuticals posts 26% revenue growth but shares fall 9% on weak guidance

ANI Pharmaceuticals reported Q2 revenues of $266 million, up 25.9% year on year, exceeding analyst expectations by 2.4%. The company beat EPS estimates but slightly missed full-year revenue guidance expectations. Despite posting the fastest revenue growth among the four generic pharmaceuticals stocks tracked, ANI's shares fell 9.1% following the results. The company's portfolio includes 116 pharmaceutical products with a focus on rare disease treatments. Generic pharmaceuticals companies as a group delivered strong Q2 results, with revenues beating consensus estimates by 2.6%. However, the sector has struggled recently, with share prices down 5.6% on average since the latest earnings announcements. The industry faces pricing pressures and thin margins but benefits from consistent demand for affordable medications.